1404063-64-4

Upstream product

• 7476-18-8 3,3-diphenyl-propionic acid ethyl ester 
• 20017-67-8 3,3-diphenylpropan-1-ol 
• 41140-53-8 1-Methanesulfonyloxy-3,3-diphenylpropane 
• 412278-02-5 rac-tert-butyl 3-hydroxy-3-methylpyrrolidine-1-carboxylate 
• 1404063-63-3 1-(3,3-diphenylpropyl)-3-methylpyrrolidin-3-ol 
• 606-83-7 3,3-Diphenylpropionic acid 
• 1404063-62-2 1-(3-hydroxy-3-methylpyrrolidin-1-yl)-3,3-diphenylpropyl-1-one 
• 763-32-6 2-methyl-1-buten-4-ol 
• 209118-78-5 (2S)-4-(4-methoxyphenoxy)-2-methylbutane-1,2-diol 
• 169310-73-0 1-methoxy-4-((3-methylbut-3-en-1-yl)oxy)benzene 
• 80352-66-5 4-mesyloxy-2-methylbutene 

Downstream Products

• 1404062-92-5 (S)-3-[(S)-1-(3,3-diphenylpropyl)-3-methylpyrrolidin-3-yl] 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 

Relevant academic research and scientific papers

Chiral heterocyclic tert-alcohol intermediate preparation method and application thereof

The invention provides a preparation method of a chiral eterocyclic tert-alcohol intermediate and a method for preparing 1,4-dihydropyridine-3,5-dicarboxylic ester derivative by the chiral eterocyclictert-alcohol intermediate. Through the method, the reac

1,4-dihydropyridine-3,5-dicarboxylate Derivatives And Preparation And Use Thereof

The present invention relates to a 1,4-dihydropyridine-3,5-dicarboxylate compound of general compound (I), a process for preparing the same, a use thereof for the manufacture of a medicament for treating and/or preventing kidney injury, cardiovascular diseases and/or endocrine diseases, as well as a pharmaceutical composition and a pharmaceutical formulation containing said compounds, wherein the definitions of R1, R2, R3, R4, R5, R6, R7, R8, m, n1, n2, p and q are the same as those defined in the description.

1,4-DIHYDROPYRIDINE -3,5-DICARBOXYLATE DERIVATIVES, PREPARATION METHODS AND USES THEREOF

The present invention relates to a 1,4-dihydropyridine-3,5-dicarboxylate compound of general compound (I), a process for preparing the same, a use thereof for the manufacture of a medicament for treating and/or preventing kidney injury, cardiovascular diseases and/or endocrine diseases, as well as a pharmaceutical composition and a pharmaceutical formulation containing said compounds, wherein the definitions of R1, R2, R3, R4, R5, R6, R7, R8, m, n1, n2, p and q are the same as those defined in the description.